Submitted by kBLASTER Team on
CLEVELAND (GLOBE NEWSWIRE) --
“For individuals who sustain spinal cord injuries, this is a milestone that could have a meaningful impact on their lives,” said Tom Williams, chairman and CEO of Parker Hannifin. “In a relatively short amount of time, we have taken what was a prototype device and readied it for full commercial launch. We are excited about the future for this new growth opportunity.”
The FDA’s clearance came after the completion of the largest exoskeleton clinical trial conducted to date in the United States
“In sponsoring such a comprehensive and landmark study, Parker demonstrated the safety and performance of the Indego technology,” said Gary Ulicny, Ph.D., president and CEO of Shepherd Center, Parker’s lead clinical partner. “Over the course of more than 1,200 individual sessions, study participants were able to use Indego to safely walk on a variety of indoor and outdoor surfaces and settings with no serious adverse events.”
Save time with kBLASTER's unique result management features of sorting, My Favorites, Saved Search and Search History to quickly find your primary predicate, multiple predicates or reference devices to build a successful 510(k) clearance strategy. Save money by enabling self-service extraction of actionable insight from more than 63,000 FDA medical device 510(k) clearance summaries, plus more than 76,000 splash pages for a total of nearly 140,000 records.
